Cell Shuttle is Cellares automated scalable cell therapy manufacturing platform with AMT designation.
Competing Products
Cellares
Cellares: Revolutionizing cell therapy manufacturing for affordable, widely available life-saving treatments.
Cellares: Revolutionizing cell therapy manufacturing for affordable, widely available life-saving treatments.
Cellares, founded with the mission to revolutionize cell therapy manufacturing, aims to make life-saving therapies affordable and widely available. The company’s core product, The Cell Shuttle, is a modular, cGMP platform designed for industrial-scale cell therapy manufacturing. Cellares offers a suite of advanced technologies including a consumable cartridge for end-to-end automation, the Cell Qᵀᴹ high-throughput QC platform, and integrated manufacturing software. Their market focus is on providing scalable, cost-effective, and high-quality solutions for the cell therapy industry.
Notable figures affiliated with Cellares include experts in biotechnology and cell therapy manufacturing. The company has attracted significant investment from leading venture capital firms. Key achievements include a 10x increase in productivity, up to 50% cost savings per batch, and a 75% reduction in process failure rates compared to conventional CDMOs. Cellares' impact is marked by its innovative approach to making cell therapies more accessible and affordable, potentially transforming patient outcomes on a global scale.
Companies similar to Cellares include Multiply Labs, Cellular Origins, Xcell Biosciences and ArsenalBio.
Cellares was founded in 2019.
Cellares' headquarters is located in South San Francisco, CA, US.
Cellares' most recent funding round was for $257M (USD) in January 2026.
As of Jan 1, 2026, Cellares has disclosed funding of $612M (USD). Undisclosed round amounts are excluded.
Cellares has 179 employees as of Feb 5, 2024.
ArsenalBio
arsenalbio.com